Profound ligand-independent kinase activation of fibroblast growth factor receptor 3 by the activation loop mutation responsible for a lethal skeletal dysplasia, thanatophoric dysplasia type II

Molecular and Cellular Biology

Volumn 16, Issue 8, 1996, Pages 4081-4087

  Webster, Melanie K ^a   D'Avis, Patricia Y ^a   Robertson, Scott C ^a   Donoghue, Daniel J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR; GLUTAMIC ACID; LEUCINE; LIGAND; LYSINE; PHENYLALANINE; PROTEIN TYROSINE KINASE; TYROSINE;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ARTICLE; AUTOPHOSPHORYLATION; BONE DYSPLASIA; CELL STRAIN 3T3; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; ENZYME ACTIVATION; LIGAND BINDING; MOUSE; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; PROTEIN DOMAIN; SIGNAL TRANSDUCTION; THANATOPHORIC DWARFISM;

EID: 0029945085     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.16.8.4081     Document Type: Article

References (35)

1. Andersen, P. E., Jr., and M. Hauge. 1989. Congenital generalised hone dysplasias: a clinical, radiological, and epidemiological survey. J Med. Genet. 26:37-44.
2. Bargmann, C. I., M. C. Hung, and R. A. Weinberg. 1986. Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185. Cell 45:649-657.
3. Bellus, G. A., T. W. Hefferon, R. I. Ortiz de Luna, J. T. Hecht, W. A. Horton, M. Machado, I. Kailila, I. McIntosh, and C. A. Francomano. 1995. Achondroplasia is defined by recurrent G380R mutations of FGFR3. Am. J. Hum. Genet. 56:368-373.
4. Bellus, G. A., I. McIntosh, E. A. Smith, A. S. Aylsworth, I. Kaitila, W. A. Horton, G. A. Greenhaw, J. T. Hecht, and C. A. Francomano. 1995. A recurrent mutation in the lyrosine kinase domain of fibroblast growth factor receptor 3 causes hypochondroplasia. Nat. Genet. 10:357-359.
5. Chen, C., and H. Okayama. 1987. High-efficiency transformation of mammalian cells by plasmid DNA. Mol. Cell. Biol. 7:2745-2752.
6. Coffin, J. D., R. Z. Florkiewicz, J. Neumann, T. Mort-Hopkins, G. W. Dorn, P. Lightfoot, et al. 1995. Abnormal bone growth and selective translational regulation in basic fibroblast growth factor (FGF-2) transgenic mice. Mol. Biol. Cell 6:1861-1873.
7. Ellis, L., E. Clauser, D. O. Morgan, M. Edery, R. A. Roth, and W. J. Rutter. 1986. Replacement of insulin receptor tyrosine residues 1162 and 1163 compromises insulin-stimulated kinase activity and uptake of 2-deoxyglucose. Cell 45:721-732.
8. 7a. Galvin, B. D., K. C. Hart, A. N. Meyer, M. K. Webster, and D. J. Donoghue. Constitutive receptor activation by Crouzon syndrome mutations in FGFR2 and FGFR2/Neu chimeras. Proc. Natl. Acad. Sci. USA, in press.
9. Gotoh, N., A. Tojo, M. Hino, Y. Yazaki, and M. Shibuya. 1992. A highly conserved tyrosine residue at codon 845 within the kinase domain is not required for the transforming activity of human epidermal growth factor receptor. Biochem. Biophys. Res. Commun. 186:768-774.
10. Hanks, S. K., and A. M. Quinn. 1991. Protein kinase catalytic domain sequence database: identification of conserved features of primary structure and classification of family members. Methods Enzymol. 200:38-62.
11. Hubbard, S. R., L. Wei, L. Ellis, and W. A. Hendrickson. 1994. Crystal structure of the tyrosine kinase domain of the human insulin receptor. Nature (London) 372:746-754.
12. Jaye, M., J. Schlessinger, and C. A. Dionne. 1992. Fibrohlast growth factor receptor tyrosine kinases: molecular analysis and signal transduction. Biochim. Biophys. Acta 1135:185-199.
13. Johnson, D. E., and L. T. Williams. 1993. Structural and functional diversity in the FGF receptor multigene family. Adv. Cancer Res. 60:1-41.
14. Keegan, K., D. E. Johnson, L. T. Williams, and M. J. Hayman. 1991. Isolation of an additional member of the fibroblast growth factor receptor family. FGFR-3. Proc. Natl. Acad. Sci. USA 88:1095-1099.
15. Keegan, K., S. Meyer, and M. J. Hayman. 1991. Structural and biosynthetic characterization of the fibroblast growth factor receptor 3 (FGFR-3) protein. Oncogene 6:2229-2236.
16. Kitayama, H., Y. Kanakura, T. Furitsu, T. Tsujimura, K. Oritani, H. Ikeda, H. Sugahara, H. Mitsui, Y. Kanayama, Y. Kitamura, et al. 1995. Constitutively activating mutations of c-kit receptor tyrosine kinase confer factorindependent growth and tumorigenicity of factor-dependent hematopoictic cell lines. Blood 85:790-798.
17. MacDonald, I. M., A. G. Hunter, P. M. MacLeod, and S. B. MacMurray. 1989. Growth and development in thanatophoric dysplasia. Am. J. Med. Genet. 33:508-512.
18. Mohammadi, M., I. Dikic, A. Sorokin, W. H. Burgess, M. Jaye, and J. Schlessinger. 1996. Identification of six novel autophosphorylation sites on fibroblast growth factor receptor 1 and elucidation of their importance in receptor activation and signal transduction. Mol. Cell. Biol. 16:977-989.
19. Mohammadi, M., C. A. Dionne, W. Li, N. Li, T. Spivak, A. M. Honegger, M. Jaye, and J. Schlessinger. 1992. Point mutation in FGF receptor eliminates phosphatidylinositol hydrolysis without affecting mitogenesis. Nature (London) 358:681-684.
20. Muenke, M., and U. Schell. 1995. Fibroblast-growth-factor receptor mutation in human skeletal disorders. Trends Genet. 11:308-313.
21. Nagata, H., A. S. Worobec, C. K. Oh, B. A. Chowdhury, S. Tannenbaum, Y. Suzuki, and D. D. Metcalfe. 1995. Identification of a point mutation in the catalytic domain of the proto-oncogcne c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc. Natl. Acad. Sci. USA 92:10550-10564.
22. Neilson, K. M., and R. E. Friesel. 1995. Constitutive activation of fibroblast growth factor receptor-2 by a point mutation associated with Crouzon syndrome. J. Biol. Chem. 270:26037-26040.
23. Orioli, I. M., E. E. Castilla, and J. G. Barbosa-Neto. 1986. The birth prevalence rates for the skeletal dysplasias. J. Med Genet. 23:328-332.
24. Peters, K., D. Ornitz, S. Werner, and L. Williams. 1993. Unique expression pattern of the FOF receptor 3 gene during mouse organogenesis. Dev. Biol. 155:423-430.
25. Rimoin, D. L. 1974. Histopathology and ultrastructure of cartilage in the chondrodystrophies. Birth Defects Original Article Series 10:1-18.
26. Rousseau, F., J. Bonaventure, L. Legeai-Mallet, A. Pelet, J. M. Rozet, P. Maroteaux, M. Le Merrer, and A. Munnich. 1194. Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasia. Nature (London) 371:252-254.
27. Rousseau, F., P. Saugier, M. Le Merrer, A. Munnich, A. L. Delezoide, P. Maroteaux, J. Bonaventure, F. Narcy, and M. Sanak. 1995. Stop codon FGFR3 mutations in thanatophoric dwarfism type 1. Nat. Genet. 10:11-12.
28. Santoro, M., F. Carlomagno, A. Romano, D. P. Bottaro, N. A. Dathan, M. Grieco, A. Fusco, G. Vecchio, B. Matoskova, M. H. Kraus, et al. 1995. Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B. Science 267:381-383.
29. Shah, K., R. Astley, and A. H. Cameron. 1973. Thanatophoric dwarfism. J. Med. Genet. 10:243-252.
30. Shiang, R., L. M. Thompson, Y. Z. Zhu, D. M. Church, T. J. Fielder, M. Bocian, S. T. Winokur, and J. J. Wasmuth. 1994. Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia. Cell 78:335-342.
31. Tavormina, P. L., D. L. Rimoin, D. H. Cohn, Y.-Z. Zhu, R. Shiang, and J. J. Wasmuth. 1995. Another mutation that results in the substitution of an unpaired cysteine residue in the extracellular domain of FGFR3 in thanatophoric dysplasia type I. Hum. Mol. Genet. 4:2175-2177.
32. Tavormina, P. L., R. Shiang, L. M. Thompson, Y. Z. Zhu, D. J. Wilkin, R. S. Lachman, W. R. Wilcox, D. L. Rimoin, D. H. Cohn, and J. J. Wasmuth. 1995 Thanatophoric dysplasia (types I and II) caused by distinct mutations in fibroblast growth factor receptor 3. Nat. Genet 9:321-328.
33. Webster, M. K., and D. J. Donoghue. 1996. Constitutive activation of fibroblast growth factor receptor 3 by the transmembrane domain point mutation found in achondroplasia. EMBO J. 15:520-527.
34. Xu, Y. F., A. N. Meyer, M. K. Webster, B. A. Lee, and D. J. Donoghue. 1993. The v-sis protein retains biological activity as a type II membrane protein when anchored hy various signal-anchor domains, including the hydrophobic domain of the bovine papilloma virus E5 oncoprotein. J. Cell Biol. 123:549-560.
35. Zhang, B., J. M. Tavare, L. Ellis, and R. A. Roth. 1991. The regulatory role of known tyrosinc autophosphorylation sites of the insulin receptor kinase domain. An assessment by replacement with neutral and negatively charged amino acids. J. Biol. Chem. 266:990-996.